{"version":"1.0","provider_name":"MedCity News","provider_url":"https:\/\/medcitynews.com","author_name":"Dr. Patricia Greenstein","author_url":"https:\/\/medcitynews.com\/author\/pgreenstein\/","title":"The Lethal Cost of Regulatory Perfection in Rare Disease - MedCity News","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"ZGeMKNC9po\"><a href=\"https:\/\/medcitynews.com\/2026\/03\/the-lethal-cost-of-regulatory-perfection-in-rare-disease\/\">The Lethal Cost of Regulatory Perfection in Rare Disease<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/medcitynews.com\/2026\/03\/the-lethal-cost-of-regulatory-perfection-in-rare-disease\/embed\/#?secret=ZGeMKNC9po\" width=\"600\" height=\"338\" title=\"&#8220;The Lethal Cost of Regulatory Perfection in Rare Disease&#8221; &#8212; MedCity News\" data-secret=\"ZGeMKNC9po\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2016\/12\/FDA_Sign__Bldg_21_at_Entrance_5204602349-e1532118797566.jpg","thumbnail_width":700,"thumbnail_height":515,"description":"Congress has already granted the FDA flexibility in evaluating therapies for rare diseases, including the use of real-world evidence and natural history data when traditional large-scale trials are not feasible. The question before the FDA now is not if those tools can be applied \u2013 they can \u2013 but if the agency has the courage to use them before more patients lose their autonomy, and ultimately, their lives, to rare disease."}